Title

The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace.

Authors

Phillips, Kathryn
Douglas, Michael

Publication Date

2018-10-01

Peer reviewed

HHS Public Access

Author manuscript

J Precis Med. Author manuscript; available in PMC 2020 March 06.

Published in final edited form as:

J Precis Med. 2018 October ; 4: .

The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace

Kathryn A. Phillips, PhD[1,2,3], **Michael P. Douglas, MS**[1]

[1]Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco

[2]Philip R. Lee Institute for Health Policy, University of California San Francisco, San Francisco

[3]Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco

Abstract

The market for next-generation sequencing technologies (NGS) has grown dramatically. Health care decision-makers need empirical evidence on market growth and future trends in order to develop appropriate strategies and policies, but little has been published about the nature and size of these trends. We provide a snapshot of market trends through 2020. We found rapid growth of clinical NGS - the global clinical NGS services market was $2.2 billion in 2015 and is forecast to reach $7.7 billion by 2020. The reproductive health NGS test market is the largest market followed by the oncology NGS test market. The largest market is for tests that sequence >50 genes but not the entire exome or genome. Markets are growing rapidly in countries outside of the US. Despite rapid NGS test growth, there are a number of key issues that will need to be addressed to facilitate appropriate future growth.

The market for next-generation sequencing technologies (NGS) has grown dramatically since the technology was first commercialized. Health care decision-makers need empirical evidence on market growth and future trends in order to develop appropriate strategies and policies, but little has been published about the nature and size of these trends.

We provide a snapshot of market trends using proprietary market trend analyses and equity research reports focusing on NGS. We used data from market trend analyses (1–3) and equity research reports from Morgan Stanley.(4–12) The market trend analyses report empirical forecasts and describe factors related to growth rates, while the equity research reports are more descriptive in nature and incorporate expert opinions from interviews and other sources. Both types of reports stated they used primary data, including soliciting assessments from NGS experts, as well as publicly available data sources, although specific

Corresponding Author Kathryn A. Phillips, Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, 3333 California Street, Box 0613, San Francisco, CA 94118, 415-502-8271 (phone), 415-502-0792 (fax), Kathryn.phillips@ucsf.edu.

SOURCE [Authors original figure, authors interpretation of data from reference 2 - Bergin J. 2016. DNA Sequencing: Emerging Technologies and Applications, and reference 3 - Bergin J. 2017. Next-Generation Sequencing: Emerging Clinical Applications and Global Markets.]

analytical methods are proprietary and thus not reported (reports were obtained through an agreement with the University of California and through personal communications).

Defining NGS Products and Clinical Markets.

The NGS products market as a whole is categorized by specific uses (clinical, research, and agricultural) and products (instruments, consumables, bioinformatics, and services). We focus particularly on clinical NGS services. Figure 1 shows the size of markets and indicates how “markets” are defined. Results are reported using the compound annual growth rate (“CAGR”), a measure of growth over multiple time periods that takes into account compounding over the time-period.

Worldwide Market Size of NGS Products and Services.

The market size for NGS products is growing. This market was nearly $5.9 billion in 2015 and is forecast to reach $13.8 billion by 2020 (18.7% CAGR).(2) A substantial and growing component of this market is represented by NGS services provided by companies that provide either raw data or a report to users. The total NGS services market was nearly $2.9 billion in 2015 and is forecast to reach $9.1 billion by 2020 (26.0% CAGR).(2) One key trend is the transition from the use of Sanger-based sequencing to NGS sequencing, with an expected decrease in the market for Sanger-based instruments and consumables of almost 5% CAGR by 2020.(2)

Worldwide Market Size of Clinical NGS Services.

Clinical NGS services is the fastest growing component of the overall NGS market (Figure 1). It encompasses diagnostics, risk prediction in cancer and other diseases (e.g. cardiovascular), therapy selection and monitoring, and screening. The global clinical NGS services market was $2.2 billion in 2015 (37% of the total market) and is forecast to reach $7.7 billion by 2020 (28.1% CAGR).(2)

Worldwide Market Size of Clinical NGS by Application.

NGS tests are used for a variety of clinical applications worldwide (Figure 1). The reproductive health NGS test market is the largest market (54%) at $1.7 billion in 2017, and is expected to reach $3.3 billion by 2022 (13.8% CAGR).(3) This consists of NIPT (the largest category), carrier screening, in vitro fertilization, and newborn screening.(3) The oncology NGS test market makes up the second largest market (27%) at $838.8 million in 2017, and is forecast to reach $4.1 billion by 2022 (37.3% CAGR).(3) Other applications include Mendelian (rare) disorders, complex diseases, and transplant diagnostics.(3) Clinical applications can be further segmented by whether they are considered “current” or “emerging” markets. Current markets include cancer, HLA typing (for transplants), Mendelian disorders, metabolic and immune disorders, prenatal testing, and IVF. Emerging markets include cardiovascular, food-borne illness, neurological, and newborn screening.(3)

Worldwide Market Size of Clinical NGS by Type of Test.

The global clinical NGS market can also be segmented by the type of test. The largest market is for tests that sequence >50 genes but not the entire exome or genome. This market is estimated to be almost $2.6 billion in 2017 and forecast to reach $5.2 billion in 2022 (15.3% CAGR).(3) However, the markets for whole exome and genome sequencing tests are rapidly increasing from their small base. The exome sequencing market is estimated at $152.2 million in 2017 and is forecast to reach a size of $1.3 billion in 2022 (53.9% CAGR), while the whole genome sequencing market is estimated at $32.9 million in 2017 but expected to reach $1.0 billion in 2022 (98.8% CAGR).(3)

North American NGS Clinical Market.

A significant portion of the NGS clinical market is based in North America (United States, Canada, and Mexico) which accounted for 43.7% ($1.3 billion) of the global clinical market in 2017. However, this percentage is forecast to decrease to 35% ($3.6 billion) in 2022. While this region's market is growing at an overall CAGR of 22.2% during this period, the rest of the world is growing at a faster rate.(3) One reason is the growth of markets in Asia, especially China as well as India.(3) Another reason is that some experts believe that early cancer detection assays (e.g. liquid biopsy) will ramp up faster outside the US.(4)

Factors Contributing to Greater Use of NGS and Future Growth.

The combination of unmet clinical needs for better tools to predict, diagnose, treat, and monitor disease and increasingly efficient sequencing technologies are major factors driving the growth of NGS(1–12). Other factors driving growth include the increased understanding of the molecular basis of disease, patient demand, industry investment, and regulations that allow marketing of tests without FDA approval.

However, within this overall growth there are important variations. For example, some experts believe that, within oncology, smaller, targeted panels will take market share away from large panels that measure hundreds of genes.(7)

Key Challenges to Be Addressed for NGS Markets.

Despite rapid NGS test growth, there are a number of key issues that will need to be addressed to facilitate future growth. The still relatively high total costs of delivering NGS test results compared with other technology platforms, and limited coverage by payers, are key challenges. NGS remains relatively costly requiring initial equipment investment, specialized workforce requirements, and time-intensive variant interpretation. Our previous work has found limited and variable coverage of NGS tests by payers,(13–18) but the recent Centers for Medicare and Medicaid national coverage determination on Medicare coverage for tumor sequencing may portend increased coverage.(19, 20) Other challenges include the need to define and document clinical utility in peer-reviewed publications and the need for laboratory markets and regulatory processes to evolve with testing. There are also concerns that patients may face high out-of-pocket costs, while current patient assistance programs that cover these programs may be unsustainable. There is a need for clinical guidelines and

consensus documents that provide evidence-based recommendations regarding test use in clinical practice.

In summary, the NGS market is growing rapidly and is expected to continue its torrid pace. However, there are significant challenges that may dampen future growth if not addressed.

Funding Support/Acknowledgement

This work was supported by National Cancer Institutes Grant (R01CA221870 (K.Phillips) and National Human Genome Research Institute Grant (R01HG007063 (K. Phillips)). Kathryn Phillips is a consultant to Illumina and has consulted with Counsyl. Michael Douglas is a consultant to Illumina.

The authors gratefully acknowledge the assistance of Steve Beuchaw (Morgan Stanley), who provided access to data and input into conception and analyses.

BIOGRAPHY

Kathryn Phillips, PhD is Professor and Founding Director, *UCSF Center for Translational and Policy Research on Personalized Medicine*. She has published >150 articles in major journals including *JAMA*, *NEJM*, and *Health Affairs;* has led NIH grants for >25 years; and serves on editorial boards for *Health Affairs* and other journals. Her work focuses on the translation of science into policy by bringing together insurers, industry, and government.

Michael Douglas, MS is Program Manager for the *UCSF Center for Translational and Policy Research on Personalized Medicine*. His research spans a variety of disciplines, including clinical and social sciences, in the academic, government and industry sectors. He has published >30 articles with expertise in genomic laboratory medicine, evidence-based reviews, personalized medicine, and reimbursement.

References

1. Next Generation Sequencing Market. Rockville, MD: Kalorama Information, 2016 September.
2. Bergin J DNA Sequencing: Emerging Technologies and Applications. Wellesley, MA: BCC Research, 2016 May.
3. Bergin J Next-Generation Sequencing: Emerging Clinical Applications and Global Markets (BIO126C). Wellesley, MA: BCC Research, 2017 June.
4. Beuchaw S, Garcia L. Life Science Tools & Diagnostics: Are Liquid Biopsies Ready for Prime Time? New York, NY: Morgan Stanley Research, 2016 April 18.
5. Beuchaw S, Garcia L. Illumina Inc.: Clinical Slowdown More Concerning Than Europe. New York, NY: Morgan Stanley Research, 2016 April 19.
6. Beuchaw S, Garcia L. Life Science Tools & Diagnostics: Molecular Diagnostics Expert Lunch Highlights. New York, NY: Morgan Stanley Research, 2016 February 25.
7. Beuchaw S, Garcia L. Life Science Tools & Diagnostics: Cancer Genomics Expert Call Highlights. New York, NY: Morgan Stanley Research, 2016 June 1.
8. Beuchaw S, Garcia L, Wachter Z, Rosenberg J. Life Science Tools & Diagnostics: AMP Diligence on ILMN, MYGN, NSTG, TTOO. New York, NY: Morgan Stanley Research, 2016 November 10.
9. Beuchaw S, Garcia L, Wachter Z, Rosenberg J. Life Science Tools & Diagnostics: Expert Feedback on ILMN, TMO, QGEN. New York, NY: Morgan Stanley Research, 2016 November 14.
10. Beuchaw S, Wachter Z. Illumina Inc.: ACSO Diligence: The Path to the TAM. New York, NY: Morgan Stanley Research, 2017 June 7.
11. Beuchaw S, Wachter Z, Rosenberg J. Life Science Tools & Diagnostics: The Precision Medicine Paradox. New York, NY: Morgan Stanley Research, 2016 December 5.

12. Beuchaw S, Wachter Z, Rosenberg J. Life Science Tools & Diagnostics: Insight Day Expert Feedback: Positioning in Diagnostics. New York, NY: Morgan Stanley Research, 2017 April 7.
13. Douglas MP, Parker SL, Trosman JR, Slavotinek AM, Phillips KA. Private Payer Coverage Policies for Whole Exome Sequencing (WES) in Pediatric Patients: Trends Over Time and Analysis of Evidence Cited Genet Med. 2018; July 12 [Epub ahead of print].
14. Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, et al. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017;15(2):219–28. [PubMed: 28188191]
15. Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips KA. Availability and payer coverage of BRCA½ tests and gene panels. Nat Biotechnol. 2015;33(9):900–2. [PubMed: 26348951]
16. Phillips KA, Deverka PA, Trosman JR, Douglas MP, Chambers JD, Weldon CB, et al. Payer coverage policies for multigene tests. Nat Biotechnol. 2017;35(7):614–7. [PubMed: 28700544]
17. Dervan AP, Deverka PA, Trosman JR, Weldon CB, Douglas MP, Phillips KA. Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. Genet Med. 2017;19(5):559–67. [PubMed: 27657682]
18. Chambers JD, Saret CJ, Anderson JE, Deverka PA, Douglas MP, Phillips KA. Examining Evidence in U.S. Payer Coverage Policies for Multi-Gene Panels and Sequencing Tests. Int J Technol Assess Health Care. 2017:1–7. [PubMed: 28528585]
19. Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, et al. Insurance coverage for genomic tests. Science. 2018;360(6386):278–9. [PubMed: 29674586]
20. Phillips KA. Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA. 2018;319(23):2379–2380. [PubMed: 29710095]

KEY POINTS

- The market for next-generation sequencing technologies (NGS) has grown dramatically, but little has been published about the nature and size of these trends.
- Health care decision-makers need empirical evidence on market growth and future trends in order to develop appropriate strategies and policies.
- Growth is highest in reproductive health, gene panels, and in countries outside the US.
- There are a number of key issues that will need to be addressed to facilitate appropriate future growth.



Figure 1:
Market Size for NGS Sequencing Products, Clinical NGS Services, and Clinical NGS Applications[2,3]